

Schedules and strategies for HPV immunization

Introduction and questions to SAGE

Andrew Pollard, SAGE Member
SAGE meeting, 18–20 October 2016

SAGE deliberations on HPV vaccines, November 2008

2

“HPV vaccines should be introduced as part of a coordinated strategy to prevent cervical cancer and other HPV-related diseases that includes...”

“The primary target population is likely to be girls within the age range of 9 or 10 through 13 years.”

Wkly Epidemiol Rep 2009, 84:11

1st position paper
published in April 2009

2009, 84, 117–132

No. 15



World Health
Organization
Organisation mondiale de la Santé

Weekly epidemiological record
Relevé épidémiologique hebdomadaire

10 APRIL 2009, 84th YEAR / 10 AVRIL 2009, 84^e ANNÉE
No. 15, 2009, 84, 117–132
<http://www.who.int/wer>

Contents

- 117 Outbreak news
 - Meningococcal disease, African meningitis belt
- 118 Human papillomavirus vaccine
WHO position paper
- 131 WHO Strategic Advisory Group of Experts on Immunization: request for nominations
- 132 WHO web sites on infectious diseases

Sommaire

- 117 Le point sur les épidémies
 - Méningocoque, ceinture de la méningite en Afrique
- 118 Vaccins anti-papillomavirus humain
Note d'information de l'OMS
- 131 Groupe stratégique consultatif d'experts de l'OMS sur la vaccination: appel aux nominations
- 132 Sites Internet de l'OMS sur les maladies infectieuses

Human papillomavirus vaccines WHO position paper

In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and vaccine combinations against diseases that have an international public health impact. These papers, which are concerned primarily with the use of vaccines in large-scale immunization programmes, summarize essential background information on their respective diseases and vaccines, and conclude with the current WHO position concerning their use in the global context. The papers have been reviewed by a number of experts within and outside WHO and, since April 2006, they have been reviewed and endorsed by WHO's Strategic Advisory Group of Experts (SAGE) on vaccines and immunization. The position papers are designed for use mainly by national public health officials and managers of immunization programmes. However, they may also be of interest to international funding agencies, the vaccine manufacturing industry, the medical community, scientific media and the public.

This is the first WHO position paper on vaccines against diseases caused by human papillomaviruses (HPVs). To complement the text and the selected references offered in this document, a comprehensive WHO background

Vaccins anti-papillomavirus humain Note d'information de l'OMS

Conformément à son mandat qui est de fournir des conseils aux Etats Membres sur les questions relatives aux politiques de santé, l'OMS publie une série de notes d'information régulièrement actualisées sur les vaccins et les associations vaccinales contre les maladies qui ont des répercussions sur la santé publique internationale. Ces notes d'information, qui portent essentiellement sur l'utilisation des vaccins dans le cadre de programmes de vaccination à grande échelle, résument les considérations générales essentielles sur les maladies et vaccins respectifs et présentent en conclusion la position actuelle de l'OMS concernant leur utilisation dans le contexte mondial. Ces notes ont été soumises à un certain nombre de spécialistes, à l'OMS et à l'extérieur, et, depuis avril 2006, sont examinées et approuvées par le Groupe stratégique consultatif d'experts de la vaccination (SAGE) de l'OMS. Elles sont principalement destinées aux responsables nationaux de la santé publique et aux administrateurs des programmes de vaccination. Toutefois, elles peuvent également présenter un intérêt pour les organismes internationaux de financement, les fabricants de vaccins, la communauté médicale, les médias scientifiques et le grand public.

Il s'agit ici de la première note d'information de l'OMS sur les vaccins contre les maladies dues au papillomavirus humain (PVH). Pour compléter ce texte et les références bibliographiques choisies présentées dans ce document, un document de travail

118

WEEKLY EPIDEMIOLOGICAL RECORD, NO. 15, 10 APRIL 2009

SAGE deliberations on HPV vaccines, April 2014

3


“SAGE reiterated the importance of targeting HPV immunization for **girls aged 9–13 years**, prior to initiation of sexual activity.”

“A **2-dose schedule** with an interval of at least 6 months between doses is recommended for girls aged **≤15 years...**”

Wkly Epidemiol Rep 2014, 89:230

2nd position paper published in October 2014

2014, 89, 465–492 No. 43

 World Health Organization
Organisation mondiale de la Santé

Weekly epidemiological record
Relevé épidémiologique hebdomadaire

24 OCTOBER 2014, 89th YEAR / 24 OCTOBRE 2014, 89^e ANNÉE
No. 43, 2014, 89, 465–492
<http://www.who.int/wer>

Contents
465 Human papillomavirus vaccines: WHO position paper, October 2014

Sommaire
465 Vaccins contre le papillomavirus humain: note de synthèse de l'OMS, octobre 2014

Human papillomavirus vaccines: WHO position paper, October 2014

Introduction
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and vaccine combinations against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes. They summarize essential background information on their respective diseases and vaccines, and conclude with the current WHO position concerning their use in the global context.

The papers are reviewed by external experts and WHO staff, and reviewed and endorsed by the WHO Strategic Advisory Group of Experts (SAGE) on immunization.

Vaccins contre le papillomavirus humain: note de synthèse de l'OMS, octobre 2014

Introduction
Conformément à son mandat qui est de fournir des conseils aux Etats Membres sur les questions relatives aux politiques sanitaires, l'OMS publie une série de notes de synthèse régulièrement actualisées sur les vaccins et les associations vaccinales contre les maladies qui ont des répercussions sur la santé publique internationale. Ces notes de synthèse, qui portent essentiellement sur l'utilisation des vaccins dans le cadre de programmes de vaccination à grande échelle, résument les considérations générales essentielles sur les maladies et vaccins concernés et présentent en conclusion la position actuelle de l'OMS concernant leur utilisation dans le contexte mondial.

Ces notes sont soumises à des experts à l'extérieur et à l'intérieur de l'OMS et sont examinées et approuvées par le Groupe stratégique consultatif d'experts sur la vaccination (SAGE) de l'OMS.


Preparation for today's session

- 1st ad-hoc expert consultation in 8–9 December 2015
- Systematic review and meta-analyses and/or modelling
 - Burden of HPV-related cancers (WHO/IARC, Lyon)
 - Burden of anogenital warts (Cochrane, London)
 - Clinical trials of HPV vaccines (9 different comparisons; Cochrane, London)
 - Observed population-level impact and herds effects of HPV immunization programmes (Univ. Laval, Québec)
 - Cost effectiveness analyses of HPV immunization programmes (Monash University Malaysia)
 - Modelling of HPV immunization strategies (Univ. Laval et al.)
- 2nd ad-hoc consultation on 30–31 August 2016

Questions for SAGE

- What is the incremental effectiveness and cost-effectiveness **for cervical cancer prevention of different HPV vaccines** based on girls-only immunization?
- What is the incremental effectiveness and cost-effectiveness **for prevention of HPV-related diseases of adolescent gender-neutral HPV immunization** compared to girls-only HPV immunization?
- What is the incremental effectiveness and cost-effectiveness **for cervical cancer prevention of immunization of multiple female cohorts** (multiple age cohorts within a defined age range) compared to single age cohort immunization of only girls aged 9–13 years or of both girls and boys aged 9–13 years?

Adolescent girls with access to HPV vaccine, 10 years after licensure... ⁶



Thank you